- Ivabradine
-
- $200.00 / 1kg
-
2023-06-26
- CAS:155974-00-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg/Month
- Ivabradine
-
- $100.00 / 1mg
-
2023-04-11
- CAS:155974-00-8
- Min. Order: 10mg
- Purity: 99%
- Supply Ability: 1000g
- Ivabradine USP/EP/BP
-
- $1.10 / 1g
-
2021-08-07
- CAS:155974-00-8
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons min
|
| | Ivabradine Basic information |
| Product Name: | Ivabradine | | Synonyms: | 3-[3-[[(8S)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methyl-amino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one;3-[3-[[(8S)-3,4-dimethoxy-8-bicyclo[4.2.0]octa-1,3,5-trienyl]methyl-methylamino]propyl]-7,8-dimethoxy-2,5-dihydro-1H-3-benzazepin-4-one;Ivabradine;Ivabridine –;7-(3-((((R)-4,5-diMethoxy-1,2-dihydrocyclobutabenzen-1-yl)Methyl)(Methyl)aMino)propyl)-2,3-diMethoxy-8,9-dihydro-5H-benzo[7]annulen-6(7H)-one;Ivabradine(Hydrochloride form);2H-3-Benzazepin-2-one, 3-[3-[[[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-;Ivabradine HCl Premix | | CAS: | 155974-00-8 | | MF: | C27H36N2O5 | | MW: | 468.59 | | EINECS: | | | Product Categories: | API | | Mol File: | 155974-00-8.mol |  |
| | Ivabradine Chemical Properties |
| Boiling point | 626.9±55.0 °C(Predicted) | | density | 1.146±0.06 g/cm3(Predicted) | | pka | 8.77±0.50(Predicted) |
| | Ivabradine Usage And Synthesis |
| Description | Ivabradine is a first selective and specific If inhibitor that
was approved by EMEA in November for symptomatic
treatment of chronic stable angina pectoris in patients with
normal sinus rhythm. This is the first agent to lower heart
rate by inhibiting the cardiac pacemaker If current. The compound
was discovered and developed by Servier and is currently
being marketed in Ireland. | | Definition | ChEBI: A member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Use
(as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure. | | Synthesis | The convergent synthesis
of ivabradine was accomplished by coupling the key
benzocylclobutanyl amine 73 with oxadioxalane 76 in an in
situ deprotection and amination as shown in Scheme 13.
For the synthesis of the key amine 73, cyano group of compound
69 is reduced with borane-THF to give amine 70 in
90% yield, which was reacted with ethyl chloroformate to
give carbamate 71 in 80% yield. Complete reduction of the
carbamate was accomplished by refluxing with LAH in THF
to give racemic methyl amine 72 in 92% yield, which was
then resolved by crystallizing with N-acetyl ¨CL-glutamic acid to give chiral salt 73. Prior to the next step, the amine is
converted to the hydrochloride salt.
The coupling partner 76 to make ivabradine was prepared
from the azepinone 74 by first reacting with bromoethyldioxalane
to give 75. The olefin in 75 was reduced by hydrogenating
with palladium/carbon catalyst at 55??C to give 76.
To the same pot, the amine 73 was added and hydrogenated
to give reductive amination product ivabradine hydrochloride
(X) in very good yields.
|
| | Ivabradine Preparation Products And Raw materials |
| Raw materials | 3H-3-Benzazepine-3-propanal, 1,2,4,5-tetrahydro-7,8-dimethoxy-2-oxo--->(S)-(4,5-diMethoxy-1,2-dihydrocyclobutabenzen-1-yl)-N-MethylMethanaMine-->3-[3-[[[(7S)-3,4-DiMethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]Methyl]MethylaMino]propyl]-1,3-dihydro-7,8-diMethoxy-H-3-benzazepin-2-one |
|